You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Cyclophosphamide-based combination therapies for autoimmunity
|
|---|---|
| Published in |
Neurological Sciences, August 2008
|
| DOI | 10.1007/s10072-008-0947-9 |
| Pubmed ID | |
| Authors |
Paola Perini, Massimiliano Calabrese, Luciano Rinaldi, Paolo Gallo |
| Abstract |
Immunomodulatory agent (IMA)-unresponsive multiple sclerosis (MS) can quickly evolve to a dramatic and irreversible disability. Treating these patients with appropriate immunosuppressive therapies can be a chance to arrest disease activity and progression. Cyclophosphamide (Cyc)-based intense immunosuppression has been successfully used to treat rapidly deteriorating, IMA-refractory MS patients. Therapeutic protocols combining Cyc and interferon beta (IFNbeta) have also been successfully applied to treat IFNbeta-unresponsive MS. The association of Cyc with other immunomodulatory drugs or monoclonal antibodies is currently being investigated in clinical trials aimed at treating severe forms of autoimmune diseases. |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 5% |
| Unknown | 21 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 18% |
| Researcher | 3 | 14% |
| Professor > Associate Professor | 3 | 14% |
| Student > Ph. D. Student | 2 | 9% |
| Student > Doctoral Student | 1 | 5% |
| Other | 4 | 18% |
| Unknown | 5 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 32% |
| Neuroscience | 4 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 14% |
| Biochemistry, Genetics and Molecular Biology | 2 | 9% |
| Agricultural and Biological Sciences | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 5 | 23% |